GP-Leds

Medical devices business Confluent accounted for a majority of NAV in a transaction involving Ampersand Capital Partners.

The firm has held the final close on its latest secondaries vehicle, which is already 20% committed to deals involving GPs such as Thomas H Lee Partners and Clearlake Capital Group.

Brian Mooney is one of seven high-level executives to have resigned from Greenhill's secondaries advisory unit in recent months.

The secondaries market is more seller-friendly than ever, allowing sponsors to push terms that surprise even seasoned pros. This is unlikely to last.

This is the second GP-led process that HarbourVest has led on a Portobello fund, after the 2015 restructuring of 2006-vintage Fund II.

The process carried out by Antin Infrastructure Partners gives more capital to fast-growing assets in its 2016-vintage Fund III, including three fibre companies.

Stephen Sloan, former head of private capital advisory at Greenhill, will lead the effort alongside another senior hire.

Strong buyer demand is allowing some GPs to drive better terms for themselves on manager-led deals, according to panellists at PEI's Women in Private Equity Forum.

The alternatives manager is raising the Special Opportunities fund alongside its flagship secondaries vehicle, which is targeting $3.75bn.

Greenhill's secondaries advisory unit, which has lost seven MDs in the space of a month, made its name executing some of the largest LP portfolio sales.